Cargando…
A Cross-Sectional Study Comparing the Prevalence of Bullous Pemphigoid Autoantibodies in 275 Cases of Type II Diabetes Mellitus Treated With or Without Dipeptidyl Peptidase-IV Inhibitors
Background: Anti-hyperglycemic drug dipeptidyl peptidase-IV inhibitors (DPP-4i) have recently been recognized as bullous pemphigoid (BP) inducing drugs. It remains uncertain whether DPP-4i induce BP-IgG autoantibodies before the onset of BP. Objective: To evaluate the effect of DPP-4i in the develop...
Autores principales: | Izumi, Kentaro, Nishie, Wataru, Beniko, Mutsuo, Shimizu, Hiroshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6607930/ https://www.ncbi.nlm.nih.gov/pubmed/31297116 http://dx.doi.org/10.3389/fimmu.2019.01439 |
Ejemplares similares
-
Preferential Reactivity of Dipeptidyl Peptidase-IV Inhibitor-Associated Bullous Pemphigoid Autoantibodies to the Processed Extracellular Domains of BP180
por: Mai, Yosuke, et al.
Publicado: (2019) -
Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid
por: Tasanen, Kaisa, et al.
Publicado: (2019) -
Bullous Pemphigoid Triggered by Thermal Burn Under Medication With a Dipeptidyl Peptidase-IV Inhibitor: A Case Report and Review of the Literature
por: Mai, Yosuke, et al.
Publicado: (2018) -
Dipeptidyl peptidase‐4 inhibitors‐associated bullous pemphigoid: A retrospective study of 168 pemphigoid and 9,304 diabetes mellitus patients
por: Kawaguchi, Yohei, et al.
Publicado: (2018) -
Bullous pemphigoid associated with use of dipeptidyl peptidase-4 inhibitor
por: Kano, Yasuhiro, et al.
Publicado: (2022)